TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
7.66
-0.13 (-1.67%)
At close: Jun 25, 2025, 4:00 PM
7.41
-0.25 (-3.26%)
Pre-market: Jun 26, 2025, 6:34 AM EDT
TransCode Therapeutics Employees
TransCode Therapeutics had 7 employees as of December 31, 2024. The number of employees decreased by 3 or -30.00% compared to the previous year.
Employees
7
Change (1Y)
-3
Growth (1Y)
-30.00%
Revenue / Employee
n/a
Profits / Employee
-$3,644,796
Market Cap
6.39M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
RNAZ News
- 4 weeks ago - TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board - PRNewsWire
- 6 weeks ago - TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported - PRNewsWire
- 7 weeks ago - TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split - PRNewsWire
- 7 weeks ago - TransCode Therapeutics Announces 1-for-28 Reverse Stock Split - PRNewsWire
- 7 weeks ago - TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer - PRNewsWire
- 2 months ago - TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting - PRNewsWire
- 3 months ago - TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 - PRNewsWire
- 3 months ago - TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering - PRNewsWire